Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty

Catheterization and Cardiovascular Interventions

Volumn 49, Issue 1, 2000, Pages 113-116

  Rashdan, Iyad ^a   Schechter, Eliot ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Coronary thrombosis; Fibrinolytic therapy; Platelet aggregation inhibitors; Thrombolytic therapy; Vascular graft occlusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEMOGLOBIN; HEPARIN; UROKINASE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; MALE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; CORONARY THROMBOSIS; DRUG EVALUATION; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033986349     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-726X(200001)49:1<113::AID-CCD27>3.0.CO;2-W     Document Type: Article

References (12)

1. Crouch MA, Nappi JM. Adjunctive intracoronary thrombolysis in complicated coronary angioplasty. Ann Pharmacother 1997;31: 1244-1246.
2. Kerensky RA, Franco EA, Bertolet BD, Thomas G, Wargovich TJ. Lysis of intravascular thrombus prior to coronary stenting using the dispatch infusion catheter. Cathet Cardiovasc Diagn 1996;38: 410-414.
3. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
4. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
5. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
6. The TIMI-IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Circulation 1993;87:38-52.
7. Mizuno K, Satomura K, Miyamoto A, Arakaw K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992;326:287-291.
8. Reeder GS, Bryant SC, Suman VJ, Holmes DR Jr. Intracoronary thrombus: still a risk factor for PTCA failure? Cathet Cardiovasc Diagn 1995;34:191-195.
9. Schachinger V, Kasper W, Zeiher AM. Adjunctive intracoronary rokinase therapy during percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:1174-1178.
10. Leopold JA, Loscalzo J. Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Coron Artery Dis 1995;6:923-929.
11. Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment. J Cardiovasc Pharmacol 1994;23: 194-102.
12. The Captive Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435.